Bisacodyl and Glucosamine Sulfate for the treatment of degenerative joint disease mainly differ in the mechanism of action, indications and dosage. 1. Mechanism of action: bivalirudin is an interleukin-1 inhibitor, which can inhibit the production and activity of IL-1, inhibit cartilage degradation and synovial inflammation and promote cartilage synthesis. Glucosamine sulfate can provide proteoglycan synthesis, supplement endogenous cartilage components, promote synovial synthesis of hyaluronic acid, inhibit enzymes that damage cartilage, and inhibit the production of superoxide radicals. 2. Indications: Bisacodyl Rhein can be used for analgesia in patients with degenerative joint diseases such as osteoarthritis with chronic pain, improve joint function, and also slow down the progression of the disease. Glucosamine sulfate is suitable for mild osteoarthritis, and is not effective in end-stage osteoarthritis with severe wear and tear of articular cartilage, and can be used selectively in symptomatic patients. 3. Dosage: Bisacodyl Rhein is usually effective 2 to 4 weeks after treatment, and it is recommended to combine it with other analgesics or NSAIDs in the initial period of administration, and the total course of treatment should not be shorter than 3 months. Glucosamine sulfate needs to be applied continuously for more than 8 weeks to show certain efficacy, and it is recommended to be taken with or after meals for those with gastric ulcers to reduce gastrointestinal discomfort. Both Bisacodyl and Glucosamine Sulfate should be used in accordance with medical advice and should not be taken privately.